A team of researchers led by the University of Bonn has now identified a promising bioactive compound that could effectively ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's disease (AD ... the brain's resident immune cells, and have identified ...

A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual cycle in female patients with sickle cell disease (SCD), according to ...

According to the American College of Allergy Asthma and Immunology, nearly one in three U.S. adults report having a seasonal ...

Both Gaucher disease and Fabry disease stem from enzyme deficiencies that cause fatty substances to accumulate in various body tissues. The role of cell and gene therapies in rare diseases Recent ...

ABC008 has been designed to treat diseases mediated by these Tc cells, including IBM and T-cell large granular lymphocytic leukemia (T-LGLL). IBM and rheumatoid arthritis overlap clinically with ...

Disease-specific human pluripotent stem cells (hPSCs) represent a new chance to unravel cellular and molecular mechanisms of neurological diseases. Along this line, we were among the first to ...

Although clear areas of overlap are known to exist between mast cell disorders and eosinophilia, it is seemingly easier to navigate each of these disease entities separately—that is, to address mast ...

Jason Mast is a general assignment reporter at STAT ... affecting key scientists who were overseeing projects on sickle cell disease, neurodevelopmental disorders, and pandemic preparedness ...

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion dependent beta-thalassemia (TDT), positioning Abu Dhabi as a ...

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...